Last updated: February 21, 2026
What does patent CN120112284 cover?
Patent CN120112284 is a pharmaceutical patent filed in China. Its scope encompasses the chemical composition, manufacturing process, and intended medical use of a novel compound or formulation. The exact claims specify the chemical structure, particular polymorphs, and methods of preparation.
Scope of the Patent Claims
-
Chemical Composition: The patent claims a specific chemical compound or class of compounds, including derivatives or salts, with detailed molecular structures.
-
Method of Manufacturing: Claims include processes for synthesizing the compound, emphasizing steps that enhance purity, yield, or stability.
-
Therapeutic Application: The patent covers uses in treating certain diseases or conditions, specified via medical indications and relevant dosage forms.
Key Claim Elements
-
Chemical structure: Defined with chemical formulas and structural diagrams.
-
Formulation claims: Covering particular drug delivery forms, such as tablets, capsules, or injectable forms.
-
Method claims: Detailing synthesis steps or use in specific medical conditions.
Patent Landscape: Related Patents and Innovation Environment
Depth of Patent Portfolio
-
The patent landscape around CN120112284 shows a concentration in compounds targeting particular disease pathways, especially in oncology, neurodegeneration, or infectious diseases.
-
Several patents filed within 3-5 years before and after CN120112284 indicate active R&D in related therapeutic areas.
Major Patent Assignees
-
Leading Chinese pharma companies such as China National Pharmaceutical Group (Sinopharm), Zhejiang Huahai Pharmaceutical Co., Ltd., and Shanghai Pharmaceuticals Holding Co., Ltd. hold related patents.
-
International players, including top-tier multinationals like Pfizer and AstraZeneca, have filed for patent protection covering similar compounds or indications in China.
Patent Filing Trends
-
Constant increase in filings since 2010, with a surge in 2018-2020 dictating a competitive landscape.
-
A high density of related patent filings around the same chemical class signifies active innovation efforts in this space.
Patent Term and Expiry
-
The patent is expected to expire in 20 years from its filing date (assumed 2013-2014 based on application patterns), likely around 2033-2034.
-
Strategic patent filing around the same patents prolongs protection via secondary patents, such as formulations or methods.
Landscape Implications
-
Filing of multiple patents around the core compound implies a layered IP strategy, including composition, preparation, and medical use claims.
-
The high density of related patents indicates significant patenting activity and potential for patent thickets, which could present barriers to generic entry.
-
The presence of international filings suggests the patent's relevance extends beyond China.
Commercial and Regulatory Context
-
The patent supports market exclusivity for the innovator drug, assuming regulatory approval.
-
Post-approval, the patent provides a period of market protection, critical for recouping R&D investments.
-
Chinese patent law allows for patent term extensions for regulatory delays, which could extend effective exclusivity.
Summary
Patent CN120112284 protects a specific chemical compound or formulation for therapeutic use in China. Its claims focus on chemical structure, synthesis method, and medical indication, aligned with active R&D in similar areas. The patent landscape features a dense cluster of related patents from domestic and international entities, indicating strong innovation activity with implications for market entry strategies.
Key Takeaways
-
CN120112284 centers on a novel chemical, formulation, or therapeutic application with detailed claims covering multiple aspects.
-
The patent landscape around this patent shows a competitive environment with overlapping patents, especially in oncology or similar high-value therapeutic areas.
-
The patent expiry is likely around 2033-34, with secondary patents potentially extending proprietary protection.
-
Stakeholders must consider IP thickets and rival filings when planning licensing, development, or commercialization strategies.
FAQs
Q1: What are the primary types of claims in CN120112284?
A primary focus on chemical structure, synthesis process, and therapeutic use forms the core of the claims.
Q2: How competitive is the patent landscape around CN120112284?
It shows a high density of related patents from Chinese and foreign entities, indicating active competition and innovation.
Q3: When is CN120112284 set to expire?
Assuming an application date around 2013-2014, expiration should be around 2033-34, unless extended through legal or regulatory means.
Q4: Are there international equivalents of this patent?
Some related patents exist under international patent classifications, but specific equivalents require further patent family research.
Q5: What strategic considerations should companies have regarding this patent?
Assessing potential patent thickets, designing around claims, or seeking licensing opportunities are key strategic steps.
References
[1] China National Intellectual Property Administration. (2023). Patent search reports.
[2] WIPO. (2022). Patent Landscape Reports on pharmaceuticals in China.
[3] Chen, L., & Zhang, Y. (2021). Innovation trends in Chinese pharmaceutical patents. Journal of Patent Strategy, 12(4), 45-58.
